Clinical Trial Update: 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

View source ↗

Summary

This clinical trial evaluating 131I-MIBG therapy for relapsed/refractory neuroblastoma is no longer available; sponsored by UT Southwestern Medical Center, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Pheochromocytoma

Drugs mentioned

• 131I-MIBG (metaiodobenzylguanidine)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Relapsed Neuroblastoma, Metastatic Pheochromocytoma | Status: NO_LONGER_AVAILABLE